NEW YORK (GenomeWeb News) — Curie-Cancer, which leads Institut Curie's industry partnerships, and the French drug developer Servier have extended an ongoing partnership focused on breast cancer research for another three years, they said today.
Institut Curie and Servier teamed up in 2005 to launch the program, which aims to identify therapeutic targets for treating triple-negative breast cancers.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: factors influencing retrotransposon integration sites, and more.

A bioethicist argues for the responsible use of germline gene editing.

Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.

Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.